Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
0.2750
-0.0150
-5.08%
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
Final hours: unlock premium data with Claim 60% OFF
Nuformix PLC (NFXN)
Add to/Remove from a Portfolio
Add to Watchlist
- Volume: 3,429,733
- Bid/Ask: 0.0000 / 0.0000
- Day's Range: 0.2615 - 0.3010
Nuformix
0.2750
-0.0150
-5.08%
- General
- Chart
- News & Analysis
- Financials
- Technical
- Forum
NFXN Cash Flow Statement
Nuformix PLC cash flow statement, assess the changes in the company's cash and cash equivalents, broken down to operating, investing and financing activities, view either quarterly or annual performance.
| Period Ending: | 2023 31/03 |
2022 31/12 |
2022 30/09 |
2022 30/06 |
|||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Period Length: | 0 Months | 0 Months | 0 Months | 0 Months | |||||||||||||||||||||||||||||||||||||||||||||
| Net Income/Starting Line | -0.169 | -0.169 | -0.211 | -0.211 | |||||||||||||||||||||||||||||||||||||||||||||
| Cash From Operating Activities | -0.047 | -0.047 | -0.169 | -0.169 | |||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||
| Cash From Investing Activities | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||
| Cash From Financing Activities | -0.018 | -0.018 | 0.132 | 0.132 | |||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||
| Foreign Exchange Effects | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||
| Net Change in Cash | -0.065 | -0.065 | -0.037 | -0.037 | |||||||||||||||||||||||||||||||||||||||||||||
| Beginning Cash Balance | 0.325 | 0.325 | 0.427 | 0.427 | |||||||||||||||||||||||||||||||||||||||||||||
| Ending Cash Balance | 0.259 | 0.259 | 0.39 | 0.39 | |||||||||||||||||||||||||||||||||||||||||||||
| Free Cash Flow | -0.091 | 0.123 | -0.117 | -0.064 | |||||||||||||||||||||||||||||||||||||||||||||
| Free Cash Flow Growth | -174.13 | 205.45 | -83.59 | 73.88 | |||||||||||||||||||||||||||||||||||||||||||||
| Free Cash Flow Yield | -2.13 | -1.94 | -6.64 | -6.83 | |||||||||||||||||||||||||||||||||||||||||||||
* In Millions of GBP (except for per share items)
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on the cash flow statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Write your thoughts about Nuformix PLC
Are you sure you want to delete this chart?
Delete Cancel
Replace the attached chart with a new chart ?
Replace Cancel
Comment Guidelines
Hargreaves Smyth
Nov 10, 2022 9:03
low risk now, 3 mill mcap to 328mill yeah ill take that thanks when we get that order in within the next month or so. Take a look at the new presentation, its excellent, shows how much we are worth on first order, and we will get offers by the sound of it. Every faith in Dan, what a man!
0
0
Criss Cross
Jul 12, 2022 8:25
I think this is one of those shares that fell to its bottom, made progress and now has everyone's interest again.
I think it is set to bounce to 1.0 fairly easy then onward and upwards depending on the company. Last raise was December and the presentation is on 22 September so Id expect good investment from there on in .
RNS
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that both of the abstracts submitted for presentation at the European Respiratory Society ("ERS") International Congress 2022 in Barcelona on September 4-6, on its lead asset NXP002, have been peer-reviewed and accepted for presentation. NXP002 is a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis ("IPF").
Commenting, Dr Julian Gilbert, Non-executive Director of Nuformix, said: "We believe NXP002 offers tremendous potential as a novel inhaled treatment for IPF and potentially other fibrosing interstitial lung diseases ("ILDs"). The Company is progressing a pre-clinical programme to demonstrate how its proprietary new form of tranilast can down regulate fibrosis and inflammation following inhalation, whilst avoiding severe side effects, which are key issues in the treatment of IPF and other ILDs. We are therefore delighted that the abstracts describing our initial work have been accepted following peer review.
Now, sounds better than good!!!
2
0
Richard Stevens
Aug 10, 2021 12:57
100% Bullish Here
3
2
Richard Stevens
Jan 29, 2020 18:18
Strong buy...so much positive news. due q1
5
5
Horun Meaj
Jan 29, 2020 18:18
What news? Never came...
2
1
Dean Grande
Sep 06, 2019 9:21
Nice to see a positive rns onwards and upwards
1
2
Andrew Robertson
Jun 24, 2019 9:17
much more to come. Hold for next waves. sales news and other milestones such as NX0002
6
0
Adrian Hampshire
Apr 26, 2019 13:12
This could seriously do multiples of current SP.
6
2
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review